Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Hepatitis C virus Stories

2013-05-21 08:29:31

ORLANDO, Fla., May 21, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global Phase 3 PROMISE study demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when...

2013-05-13 08:27:15

However, Recent Changes in Brazil and Argentina are Expected to Drive a Shift in Treatment of HCV Genotype 1 Infections, According to a New Report From Decision Resources BURLINGTON, Mass., May 13, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of hepatitis C virus (HCV) patients in Brazil, Mexico and Argentina rely entirely on government-sponsored medical programs to...

2013-05-06 08:30:54

- Interferon-free, direct-acting antiviral combination therapy currently in Phase 3 development NORTH CHICAGO, Ill., May 6, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its investigational direct-acting antiviral (DAA) combination with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA). The designation is based, in part, on...

2013-04-26 16:21:58

Gilead Sciences Leads the Way in Delivering the First All Oral Treatment for HCV NEW YORK, April 26, 2013 /PRNewswire/ -- Citeline®, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials has just published an exclusive whitepaper examining the current progress towards a remarkable improvement in the medical treatment for HCV. (Logo: http://photos.prnewswire.com/prnh/20120917/NE75453LOGO ) With news of the impending breakthrough...

2013-04-26 08:23:48

BEERSE, Belgium, April 26, 2013 /PRNewswire/ -- - OPTIMIZE study results presented at EASL show similar sustained virological response (SVR12) rates in patients with fibrosis or cirrhosis receiving an INCIVO(R)(telaprevir) combination treatment twice daily versus every eight hours - Janssen Infectious Diseases-Diagnostics BVBA (Janssen), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

2013-04-23 20:21:48

-- STARTVerso(TM)1 data presented in treatment-naïve patients with genotype-1 hepatitis C treated with investigational faldaprevir and pegylated interferon/ribavirin1,2 -- Statistically significant viral cure rates achieved versus placebo plus PegIFN/RBV with similar rates of treatment discontinuation -- The majority of patients qualified for shorter treatment duration of 12 weeks...

2013-04-23 12:32:03

- STARTVerso(TM)1 data presented in treatment-naive patients with genotype-1 hepatitis C treated with investigational faldaprevir and pegylated interferon/ribavirin RIDGEFIELD, Conn., April 23, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from the pivotal Phase 3 STARTVerso(TM)1 trial of faldaprevir (BI 201335) in combination with pegylated interferon and ribavirin (PegIFN/RBV). In previously untreated patients with genotype-1...

2013-04-23 08:32:37

- 96 percent of treatment-naive patients and 93 percent of prior null responders treated with AbbVie's investigational IFN-free, triple-DAA combination therapy achieve SVR24 AMSTERDAM, April 23, 2013 /PRNewswire/ -- (NYSE: ABBV) - Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1...

2013-04-08 08:30:51

RIDGEFIELD, Conn., April 8, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced that data from its pivotal STARTVerso(TM) 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress(TM) 2013: 48th Annual Meeting of the European Association for the Study of the Liver (EASL), taking place from April 24-28 in Amsterdam, The Netherlands. The STARTVerso(TM) 1 trial evaluated faldaprevir (BI 201335), an investigational...

2013-04-08 04:20:53

CORK, Ireland, April 8, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), which will take place April 24 to 28 in Amsterdam, The Netherlands. These data presentations will include primary efficacy and safety results from the Phase 3 QUEST-1 study of...


Latest Hepatitis C virus Reference Libraries

11_c18ff18c314281da28f1d18fa4357602
2011-01-20 19:28:48

Hepatitis E virus is an infective organism. The viral particles are 27 to 34 nanometers in diameter. They are non-enveloped and contain a single-strand of positive-sense RNA which is approximately 7300 bases in length. The virus was first visualized in 1983 and molecularly cloned in 1990. Previously it was classified in the family Caliciviridae. Its genome more closely resembles the rubella virus and is now classified as the only member of the genus Hepevirus which has not yet been...

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (2 articles) »